Noninterference of rotavirus vaccine with measles-rubella vaccine at 9 months of age and improvements in antirotavirus immunity: A randomized trial

Journal of Infectious Diseases

Volumn 213, Issue 11, 2016, Pages 1686-1693

  Zaman, K ^a   Fleming, Jessica A ^b   Victor, John C ^b   Yunus, Mohammad ^a   Bari, Tajul Islam A ^c   Azim, Tasnim ^a   Rahman, Mustafizur ^a   Mowla, Syed Mohammad Niaz ^a   Bellini, William J ^d   McNeal, Monica ^e   Icenogle, Joseph P ^d   Lopman, Ben ^d   Parashar, Umesh ^d   Cortese, Margaret M ^d   Duncan Steele, A ^b,f   Neuzil, Kathleen M ^b,g  

^a INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

^b PATH   (United States)

^c Directorate General of Health Services   (Bangladesh)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^f BILL AND MELINDA GATES FOUNDATION   (United States)

^g University of Maryland School of Medicine Center for Vaccine Development   (United States)

Author keywords

Measles vaccine; Non interference.; Rotavirus vaccine; Rubella vaccine; Vaccine co administration

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MEASLES ANTIBODY; MEASLES RUBELLA VACCINE; NEUTRALIZING ANTIBODY; ROTAVIRUS ANTIBODY; ROTAVIRUS VACCINE; RUBELLA ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY; MEASLES VACCINE; RUBELLA VACCINE; VACCINE;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BANGLADESH; BLOOD ANALYSIS; CONTROLLED STUDY; DIARRHEA; DRUG COMPETITION; FECES ANALYSIS; FEMALE; FEVER; HUMAN; HUMAN EXPERIMENT; INFANT; INTUSSUSCEPTION; IRRITABILITY; LOSS OF APPETITE; MALE; MEASLES; MEASLES VIRUS; NORMAL HUMAN; OPEN STUDY; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ROTAVIRUS; ROTAVIRUS INFECTION; RUBELLA; RUBELLA VIRUS; SEROCONVERSION; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VIRUS IMMUNITY; VIRUS SHEDDING; VOMITING; BLOOD; DOSE RESPONSE; IMMUNITY; IMMUNOLOGY; VACCINE IMMUNOGENICITY;

ANTIBODIES, VIRAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HUMANS; IMMUNITY; IMMUNOGENICITY, VACCINE; INFANT; MEASLES VACCINE; ROTAVIRUS; ROTAVIRUS VACCINES; RUBELLA VACCINE; VACCINES, COMBINED;

EID: 84978710298     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw024     Document Type: Article

References (43)

1. Kotloff KL, Nataro JP, Blackwelder WC, et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet 2013; 382:209-22.
2. Tate JE, Burton AH, Boschi-Pinto C, et al. 2008 estimate of worldwide rotavirusassociated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-Analysis. Lancet ID 2012; 12:136-41.
3. Zaman K, Yunus M, Faruque ASG, et al. Surveillance of rotavirus in a rural diarrhoea treatment centre in Bangladesh, 2000-2006. Vaccine 2009; 27(suppl 5): F31-4.
4. Madhi SA, Cunliffe NA, Steele AD, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010; 362:289-98.
5. Zaman K, Dang DA, Victor JC, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 376:615-23.
6. Armah GE, Sow SO, Breiman RF, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 376:606-14.
7. Gatchalian S, Yao Y, Zhou B, et al. Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants. Vaccine 2008; 26:2234-41.
8. Victor JC, Gatchalian S, Yao Y, et al. Corrigendum to "Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants" [Vaccine 26 (2008) 2234-2241] Vaccine 2014; 32:306-8.
9. Zaman K, Yunus M, Sack D, et al. Effectiveness of the oral human rotavirus vaccine (Rix4414) in Bangladeshi infants: a cluster-randomized trial [abstract 39]. Presented at: Tenth International Rotavirus Symposium, Bangkok, Thailand, 2012.
10. Dennehy PH, Brady RC, Halperin SA, et al. Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine. Pediatr Infect Dis J 2005; 24:481-8.
11. O'Ryan M. Rotarix (RIX4414): An oral human rotavirus vaccine. Expert Rev Vaccines 2007; 6:11-9.
12. Cohen BJ, Audet S, Andrews N, Beeler J. Plaque reduction neutralization test for measles antibodies: Description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination. Vaccine 2007; 26:59-66.
13. Chen RT, Markowitz LE, Albrecht P, et al. Measles antibody: reevaluation of protective titers. J Infect Dis 1990; 162:1036-42.
14. Bernstein DI, Smith VE, Sherwood JR, et al. Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12. Vaccine 1998; 16:381-7.
15. Knowlton DR, Spector DM, Ward RL. Development of an improved method for measuring neutralizing antibody to rotavirus. J Virol Methods 1991; 33:127-34.
16. Ward RL, Bernstein DI, Shukla R, et al. Effects of antibody to rotavirus on protection of adults challenged with a human rotavirus. J Infect Dis 1989; 159:79-88.
17. Rahman M, Sultana R, Ahmed G, et al. Prevalence of G2P[4] and G12P[6] rotavirus, Bangladesh. Emerg Infect Dis 2007; 13:18-24.
18. Helfand RF, Kebede S, Gary HE Jr., Beyene H, Bellini WJ. Timing of development of measles-specific immunoglobulin M and G after primary measles vaccination. Clin Diagn Lab Immunol 1999; 6:178-80.
19. Carson MM, Spady DW, Albrecht P, et al. Measles vaccination of infants in a wellvaccinated population. Pediatr Infect Dis J 1995;14:17-22.
20. Wijesinghe PR, Abeysinghe MRN, Yoksan S, et al. Safety and immunogenicity of live-Attenuated Japanese encephalitis SA 14-14-2 vaccine co-Administered with measles vaccine in 9-month-old infants in Sri Lanka. Vaccine 2014; 32:4751-7.
21. Whittle HC, Campbell H, Rahman S, Armstrong JR. Antibody persistence in Gambian children after high-dose Edmonston-Zagreb measles vaccine. Lancet 1990; 336:1046-8.
22. Martins C, Garly ML, Bale C, et al. Measles antibody levels after vaccination with Edmonston-Zagreb and Schwarz measles vaccine at 9 months or at 9 and 18 months of age: a serological study within a randomised trial of different measles vaccines. Vaccine 2013; 31:5766-71.
23. Fowlkes A, Witte D, Beeler J, et al. Persistence of vaccine-induced measles antibody beyond age 12 months: a comparison of response to one and two doses of Edmonston-Zagreb measles vaccine among HIV-infected and uninfected children in Malawi. J Infect Dis 2011; 204:S149-57.
24. Davidson GP, Hogg RJ, Kirubakaran CJ. Serum and intestinal immune response to rotaviral enteritis in children. Infect Immun 1983; 40:447-52.
25. Zaman K, Sack DA, Yunus M, et al. Successful co-Administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age. Vaccine 2009; 27:1333-9.
26. Ciarlet M, Sani-Grosso R, Yuan G, et al. Concomitant use of the oral pentavalent human-bovine reassortant rotavirus vaccine and oral poliovirus vaccine. Pediatr Infect Dis J 2008; 27:874-80.
27. Dennehy PH, Bertrand HR, Silas PE, Damaso S, Friedland LR, Abu-Elyazeed R. Coadministration of RIX4414 oral human rotavirus vaccine does not impact the immune response to antigens contained in routine infant vaccines in the United States. Pediatrics 2008; 122:e1062-6.
28. Tregnaghi MW, Abate HJ, Valencia A, et al. Human rotavirus vaccine is highly efficacious when coadministered with routine expanded program of immunization vaccines including oral poliovirus vaccine in Latin America. Pediatr Infect Dis J 2011; 30:e103-8.
29. Salinas B, Perez SI, Linhares AC, et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: A randomized, placebo-controlled trial in Latin American infants. Pediatr Infect Dis J 2005; 24:807-16.
30. Nascimento Silva JR, Camacho LAB, Siqueira MM, et al. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella. Vaccine 2011; 29:6327-34.
31. Steele AD, De VB, Tumbo J, et al. Co-Administration study in South African infants of a live-Attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines. Vaccine 2010; 28:6542-8.
32. World Health Organization. Rotavirus vaccines-WHO position paper-January 2013. WEER 2013; 88:49-64.
33. Patel M, Patzi M, Pastor D, et al. Effectiveness of monovalent rotavirus vaccine in Bolivia: case-control study. BMJ 2013; 346:f3726.
34. De Palma O, Cruz L, Ramos H, et al. Effectiveness of rotavirus vaccination against childhood diarrhoea in El Salvador: case-control study. BMJ 2010; 340:c2825.
35. Patel M, Pedreira C, De Oliveira LH, et al. Association between pentavalent rotavirus vaccine and sever rotavirus diarrhea among children in Nicaragua. JAMA 2009; 301:2243-51.
36. Groome M, Page N, Cortese M, et al. Effectiveness of monovalent human rotavirus vaccine against admission to hospital for acute rotavirus diarrhoea in South African children: a case-control study. Lancet Infect Dis 2014; 14:1096-104.
37. Neuzil KM, Zaman K, Victor JC. A proposed framework for evaluating and comparing efficacy estimates in clinical trials of new rotavirus vaccines. Vaccine 2014; 32(suppl 1):A179-84.
38. Desselberger U. Rotaviruses. Virus Res 2014; 190:75-96.
39. Angel J, Franco MA, Greenberg HB. Rotavirus immune responses and correlates of protection. Curr Opin Virol 2012; 2:419-25.
40. Patel MM, López-Collada VR, Bulhões MM, et al. Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. N Engl J Med 2011; 364:2283-92.
41. Patel MM, Haber P, Baggs J, Zuber P, Bines JE, Parashar UD. Intussusception and rotavirus vaccination: a review of the available evidence. Expert Rev Vaccines 2009; 8:1555-64.
42. Buttery JP, Danchin MH, Lee KJ, et al. Intussusception following rotavirus vaccine administration: post-marketing surveillance in the National Immunization Program in Australia. Vaccine 2011; 29:3061-6.
43. Loughlin J, Mast C, Doherty M, Wang F, Wong J, Seeger J. Postmarketing evaluation of the short-term safety of the pentavalent rotavirus vaccine. Pediatr Infect Dis J 2012; 31:292-6.